Ontin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ontin

Quick Facts

Property Description
Active Ingredient Cetirizine Hydrochloride
Form Tablets, Syrup, Oral Solution
Pharmacological Class Second-generation H1 Antihistamine
Common Use Relief of Allergic Symptoms/Inflammation
Origin Synthetic, Piperazine derivative

What is Ontin? Definitional Identity and Antihistamine Class

Ontin is the medicinal entity containing the active ingredient Cetirizine Hydrochloride (INN), which is formally classified as a second-generation H1 Antihistamine. This categorization places it among selective compounds engineered to manage allergic responses. As a synthetic derivative, it belongs to the piperazine family of chemical compounds. Its defining characteristic is its role as a highly selective peripheral H1-receptor antagonist, utilized for the treatment of allergic conditions.

The drug is characterized by a rapid onset and sustained efficacy in symptom control. This design is critical for achieving a long duration of action (up to 24-hour relief) and providing effective relief while mitigating the systemic sedative effects often associated with less selective agents like older, first-generation antihistamines.


Composition, Origin, and Available Forms

The medication's fundamental composition is centered on Cetirizine Hydrochloride, a single active ingredient product. Chemically, Cetirizine is a racemic compound—a mixture containing both the active Levocetirizine enantiomer and a less active counterpart. Ontin is typically an Over-the-Counter (OTC) preparation, positioned for broad use across different age groups. It is primarily available for systemic use via the oral route of administration, distributed in various dosage forms including film-coated tablets, oral solution, and syrup. The variety of forms, particularly liquids like the syrup and oral solution, ensures suitability for a wide range of target audiences, including adults and pediatric volunteers.


How Ontin's Mechanism Relates to General Allergic Relief

Ontin's therapeutic benefit is derived from its core physiological action: the selective blocking of histamine. Histamine is the potent inflammatory mediator released by the body during an immune response to allergens. By acting as an H1-receptor antagonist, the drug prevents this mediator from initiating the allergic cascade. This mechanism is critical for mitigating general allergic inflammation, serving the primary therapeutic purpose of providing 24-hour relief from common allergic manifestations. These symptoms include pruritus (itching), rhinorrhea (runny nose), and frequent sneezing that characterize conditions like allergic rhinitis and chronic urticaria, a typical use scenario. The clinical efficacy of Cetirizine for these generalized allergic conditions is recognized.

What side effects are possible with Ontin?

Possible Side Effects and Safety Information

The safety profile of Ontin (Cetirizine Hydrochloride) is formally established by regulatory bodies, classifying potential adverse reactions based on their statistical frequency in clinical data.

Adverse effects are documented across several System-Organ Classes, including Nervous System Disorders (e.g., somnolence, headache, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, nausea).

Common reactions, occurring in more than 1 in 100 people, typically include somnolence, fatigue, and dry mouth. Uncommon reactions include agitation, pruritus (itching), and diarrhea.

Serious Adverse Reactions

Regulatory documents highlight Rare events, which affect less than 1 in 1,000 people. These include hypersensitivity reactions, such as anaphylactic shock (a Very Rare event), and instances of abnormal hepatic function characterized by elevated liver enzymes and bilirubin, which usually resolve upon discontinuation. The FDA has also noted rare reports of severe pruritus that may occur after stopping long-term daily use.

Safety Constraints and Specific Populations

Ontin is contraindicated in individuals with severe renal impairment (creatinine clearance below 10 mL/min). Caution is recommended in older adults due to potentially decreased renal clearance and in patients with risk factors for urinary retention. Furthermore, concurrent use with alcohol or other Central Nervous System (CNS) depressants may lead to an additive reduction in alertness and impairment of performance, a key safety limitation documented in labeling.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The extended-release nature of Ontin (representing the controlled-release opioid class) poses a significant risk for a serious, life-threatening, or fatal overdose. The overdose profile is defined by severe respiratory depression (slowed, shallow, or difficult breathing) and profound Central Nervous System (CNS) depression.

Documented Overdose Symptoms

Overdose manifestations, as described in regulatory documents, include:

  • Life-threatening or fatal respiratory depression
  • Profound sedation or unconsciousness
  • Coma and death
  • Slow or weak heartbeat
  • Pinpoint pupils (though marked mydriasis may be seen with worsening hypoxia)

Overdose Risk Factors and Circumstances

Risk is substantially increased when the tablet is crushed, chewed, cut, or dissolved, leading to the rapid release and absorption of a potentially fatal dose. Accidental ingestion of even a single dose, especially by children, can be fatal. The risk is also greater upon initiation, after a dose increase, or when used concomitantly with other CNS depressants, including alcohol or benzodiazepines.

Required Emergency Actions

Immediate medical help is required if an overdose is suspected or if you experience any severe symptoms such as trouble breathing, extreme sleepiness, inability to wake up, or mental changes. You must get emergency help right away by contacting emergency services or going to the nearest Emergency Department. Patients should discuss the availability and use of naloxone (an opioid overdose reversal agent) with their healthcare provider.

Therapeutic Uses of Ontin

Ontin is a medication applied across therapeutic domains where additional symptomatic support is needed, primarily for managing the symptoms of Major Depressive Disorder (MDD) in adults. This medication is commonly used across conditions presenting with acute episodes, where it helps address symptom clusters that may become intense or disruptive.

The primary therapeutic use includes managing Major Depressive Disorder. It is also considered relevant for easing symptoms related to heightened physiological activity and systemic imbalance. This supportive relief contributes to improved comfort during periods of heightened symptoms and is relevant for easing symptoms that interfere with daily functioning. It supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

“The use of Ontin supports general well-being during symptomatic phases, helping patients cope more steadily.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Ontin (Cetirizine Hydrochloride) use is strictly governed by population-specific eligibility criteria defined in official regulatory labeling.

Contraindications

The medicine is strictly contraindicated and must not be used by patients with a known history of hypersensitivity to the active ingredient, Cetirizine Hydrochloride, its excipients, or related compounds such as Hydroxyzine. Absolute non-eligibility also applies to patients diagnosed with severe renal impairment (creatinine clearance less than 10 mL/min), as the drug is cleared primarily by the kidneys.

Age-Related Eligibility

Ontin is typically approved for use in adults and adolescents (ge 12 years). For children, eligibility is limited; while some liquid formulations are approved down to 6 months for specific indications, the tablet form is not recommended for children under 6 years of age due to inappropriate dose adaptation. In older adults (ge 65 years), dose adjustment is typically recommended due to potential age-related decrease in kidney function.

Conditional Use and Restrictions

Use is conditional for patients with moderate renal impairment or hepatic impairment, as these conditions necessitate a dose reduction as stated in the label. The medicine is generally not recommended during pregnancy or lactation, and caution is explicitly advised for individuals with a predisposition to urinary retention or those with epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ontin (Cetirizine Hydrochloride) has officially documented interaction patterns based on regulatory labeling, classified primarily as pharmacodynamic and pharmacokinetic. All statements reflect the findings in authoritative government sources.


Documented Interaction Patterns

Interaction Type Interacting Substance(s) Official Regulatory Finding
Formal Contraindication Hydroxyzine Co-administration is contraindicated due to potential for cross-hypersensitivity and structural relation.
Pharmacodynamic (PD) Risk Alcohol, CNS Depressants (e.g., Sedatives) Use with these substances may result in additive impairment of Central Nervous System (CNS) function and alertness.
Pharmacokinetic (PK) Effect Theophylline (400 mg dose) Co-administration results in a documented 16% decrease in Cetirizine clearance.

Population and General Constraints

Regulatory information notes that no clinically significant pharmacokinetic interactions were observed with common co-administered medicines such as Azithromycin, Erythromycin, Ketoconazole, or Pseudoephedrine. However, the elimination of Cetirizine is notably altered in certain populations, which affects overall exposure. In the geriatric population and in individuals with hepatic impairment, the elimination half-life is documented as prolonged by 50%, with total body clearance reduced by 40%. The official labels do not specify any mandatory time-based separation rules for administration.

Mechanism of Action

Blocking the Peripheral Histamine Pathway

The mechanism of Ontin is defined by its highly selective antagonism of the Histamine H1 -receptor located outside the central nervous system (CNS). The molecule binds to these receptors, preventing the inflammatory mediator histamine from binding, thereby interrupting the signaling cascade at its initial molecular step. This action initiates a signal modulation sequence within the histaminergic system.


Modulation of Vascular Permeability

The action on H1 -receptors located on endothelial cells directly influences the vascular permeability cascade. By blocking these receptors, the mechanism maintains endothelial cell tight junction integrity, which reduces fluid and protein extravasation. This targeted interference reduces the histamine-mediated increase in fluid and protein extravasation into surrounding tissues.


Inhibition of Peripheral Sensory Nerve Stimulation

The mechanism extends to the H1 -receptors found on peripheral sensory nerve endings. Antagonism at this site suppresses the nerve-stimulating signal that histamine normally triggers, thereby blocking the afferent neural transmission. This selective peripheral focus allows for targeted pathway interference with minimal crossover into the CNS, which contributes to selective peripheral H1 -receptor activity.

Dosage and Administration Information

How to Use Ontin: Official Administration Guidelines

The usage of Ontin (Cetirizine Hydrochloride) is structured by official instructions that define the administration routes, dosing schedules, and requirements for patient populations. The medication is generally taken as a standard 10 mg dose once daily, and this regimen provides relief over a 24-hour period.


Official Administration Scope

Feature Official Instruction
Route of Administration Primarily Oral (tablets, solution, syrup). Intravenous (IV) is also an approved systemic route for injectable formulations.
Dosing Schedule Standard dose for adults and adolescents (12 years) is 10 mg once daily. The maximum recommended oral dose is 10 mg in 24 hours.
Timing in Relation to Meals May be taken with or without food, as food intake does not alter the overall extent of absorption.
Preparation Requirements Tablets must be swallowed whole with liquid. Oral liquids require precise measurement using a dosing cup or syringe.
Special Procedural Conditions A three-day washout period is required before allergy skin testing to prevent interference with the test results.

Population-Specific Dosing Rules

Age-Group Administration:

  • Pediatric: Tablets are generally unsuitable for children under 6 years due to the difficulty in making necessary dose adjustments. Children aged 6–11 years may receive 10 mg once daily or 5 mg twice daily.
  • Older Adults: A dose reduction to 5 mg once daily is often recommended, especially if renal function is reduced.

Renal Impairment: Dose adjustment is mandatory. For moderate impairment, the dose is typically reduced to 5 mg once daily; for severe impairment, the dose is often reduced to 5 mg once every two days.

Missed Dose: In the event of a missed dose, the standard protocol is to avoid taking a double dose and instead wait for the next scheduled single dose to resume the regular once-daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes research evidence on the drug's area of research focus and evaluated outcomes in managing acute pain, including for individuals who may not be responsive to traditional non-steroidal anti-inflammatory drugs (NSAIDs).

Summary of Study Hypothesis

Research examined the effects of EP2 and EP4 receptor modulation. Trial designs were based on the hypothesis of EP2 and EP4 receptor involvement in pain and inflammation.

Evidence from Clinical Trials on Acute Pain

Clinical research focused on the compound's effect as evaluated in various types of acute pain studies.

Post-Surgical Pain Management

A double-blind, randomized, placebo-controlled clinical trial evaluated the drug in 150 patients experiencing moderate-to-severe pain following third molar extraction.

  • One key study focused on post-surgical dental pain, where researchers evaluated the speed of onset.
  • A statistically significant difference in analgesic effect was reported when compared to placebo.
  • The reported primary endpoint in the post-surgical study was the sum of pain intensity differences ( SPID) over 6 hours.

Acute Musculoskeletal Pain

Another trial examined 250 participants with acute lower back pain and findings included the evaluation of pain scores over a 7-day course. The data was assessed to evaluate the drug's observed effects. The primary outcome measure used was the Visual Analog Scale ( VAS).

Secondary Use: Migraine Episodes

A randomized controlled trial (RCT) also examined outcomes related to severe migraine episodes, including headache duration.

  • A difference in reported outcomes was noted compared to the Ibuprofen group, specifically related to associated nausea.
  • Researchers noted a potential differential effect beyond general analgesia, and further investigation was suggested.

Observation Period and Tolerability

Studies on this drug have primarily focused on short-term use, and data on long-term observation is currently limited. The tolerability profile described in these acute pain settings was reported. The evidence provides initial data from studies.

Key Studies & References Short-Term Evaluation of Ontin for Acute Musculoskeletal Lower Back Pain: A Phase 3 Study

Frequently Asked Questions (FAQ)

Common questions about Ontin (FAQ)

Q: How quickly can I expect the effects of Ontin to start?

A: Official documentation indicates that the active ingredient, cetirizine, is associated with a rapid onset of action in relieving allergy symptoms. Studies have reported the initial effects are often observed within 20 to 60 minutes following the administration of the medicine.


Q: What should I do if I miss a dose of Ontin?

A: Regulatory guidelines describe that if a dose is missed, individuals should avoid taking a double dose to compensate. The guidance is to wait and resume the routine by taking the next single dose at the scheduled time, in line with the once-daily administration schedule.


Q: Are there any common foods or drinks I should avoid while taking Ontin?

A: The official product information notes that the medicine can be taken with or without food. However, use with alcohol and other Central Nervous System (CNS) depressants is discouraged by regulatory bodies due to the potential for additive impairment of alertness.


Q: What is the difference between Ontin and other similar medicines?

A: Ontin is officially classified as a second-generation H1 Antihistamine. This class of medicine is engineered to be highly selective for certain peripheral receptors. This design aims to provide allergy relief while generally having less systemic sedative effects compared to older, first-generation antihistamines.


Q: Are the side effects of Ontin permanent?

A: Adverse effects listed in official documents are generally described as reversible. For instance, instances of abnormal liver function reported were noted to typically resolve upon discontinuation of the drug. Any experience with side effects is a topic for discussion with a healthcare professional.


Q: Can Ontin affect my sleep patterns?

A: Somnolence (drowsiness) is listed in official documents as a common side effect of Ontin. While some objective measurements in studies have shown no notable effect on sleep onset, the drug's documented central nervous system effects may influence the user's feeling of alertness.


Q: Is Ontin known to cause weight gain?

A: Official regulatory documents list weight increase as a rare side effect, meaning it may affect up to 1 in 1,000 people. Increased appetite is also listed as a possible side effect, though its exact frequency could not be reliably estimated from available data.


Q: Does Ontin require special monitoring or tests while taking it?

A: The medicine does not generally require standard routine testing for all users. However, special monitoring is often indicated for individuals with kidney or liver disease, as regulatory guidelines note that these conditions may necessitate attention to administration quantity.


Q: What are the long-term effects of taking Ontin?

A: Studies on this drug have primarily focused on short-term use. Official documents note that following long-term daily use, typically lasting six months or more, there have been rare reports of severe itching (pruritus) occurring after stopping the medicine.


Q: Does Ontin cause dependency or withdrawal symptoms?

A: Official documents do not define the drug as causing addiction or a formal withdrawal syndrome. However, they do document the rare occurrence of severe itching upon discontinuation after long-term daily use.


Q: Are headaches a common side effect of Ontin?

A: Headache is specifically listed in official documentation as a common side effect of Ontin. This means that statistically, it is reported to occur in more than 1 in 100 people taking the medicine.


Q: What happens if I take too much Ontin?

A: Official documentation states that signs of overdose may include marked symptoms of extreme sleepiness or drowsiness. Other reported symptoms in some cases include agitation or a rapid heartbeat. In the event of a suspected overdose, regulatory information recommends contacting a Poison Control Center or seeking emergency medical attention.


Q: Is it possible to be allergic to Ontin?

A: Yes, regulatory documents list hypersensitivity reactions as possible adverse events, including very rare occurrences of severe reactions like anaphylactic shock. The medicine is strictly contraindicated and should not be used by individuals with a known allergy to the active ingredient.


Q: Can Ontin cause changes in appetite?

A: Official documents list increased appetite as a possible side effect, but the frequency with which it occurs is not reliably known from the data collected so far. Separately, weight increase is documented as a rare side effect.


Q: Are there any dietary restrictions mentioned in the official Ontin documents?

A: The official product information notes that the drug can be taken with or without food. There are no specific dietary restrictions documented in the core regulatory labels, but caution regarding the co-administration of alcohol is explicitly noted.


Q: What does the term 'pharmacovigilance' mean for a drug like Ontin?

A: Pharmacovigilance refers to the process of monitoring the safety of a medicine after it has been approved and marketed. Official regulatory bodies use this system to collect, assess, and prevent adverse effects, ensuring the drug’s benefit-risk profile remains acceptable.


Q: Why is it important to read the patient information leaflet for Ontin?

A: Official regulatory requirements mandate that the patient information leaflet contains the most important safety information. This includes the potential risks (side effects), necessary warnings, and guidance on administration to ensure the patient is fully informed.


Q: Is it safe to drink alcohol while using Ontin?

A: Regulatory documents state that using Ontin with alcohol may result in additive impairment of Central Nervous System (CNS) function and alertness. This combination has been associated with an increased potential for reduced concentration and reaction time. Use of the medicine requires attention to these documented warnings.


Q: What if I'm already taking supplements or herbal products with Ontin?

A: Regulatory sources generally note that there is limited formal information available on interactions between this medicine and many herbal remedies or supplements. It is important to consider any supplement that might independently cause effects like sleepiness or dry mouth.


Q: Does Ontin interact with birth control pills?

A: No major clinically significant interaction between Ontin's active ingredient and hormonal contraceptives (birth control pills) has been widely reported or formally documented in core regulatory labels.


Q: What should I know about driving or operating machinery while on Ontin?

A: Regulatory labels advise users to use caution when driving a motor vehicle or operating machinery. This is because the medication may cause drowsiness or somnolence, which can temporarily impair cognitive function and motor skills.


Q: Is Ontin covered by most insurance plans?

A: The active ingredient in Ontin is typically classified as an Over-the-Counter (OTC) drug, which means it is available without a prescription. Its coverage by insurance plans is typically governed by the payer's specific policy regarding non-prescription medicines.


Q: Is it okay to take Ontin with my morning coffee?

A: No specific interaction between the drug and caffeine is formally documented in regulatory labels. However, because the drug may cause drowsiness, users should be mindful of how their body reacts to the combination of the stimulant (caffeine) and the drug.


Q: Does Ontin interact with medications for diabetes?

A: Specific drug interaction studies with common anti-diabetic medications are generally not detailed in the core regulatory labels. No major, clinically significant interaction that would affect the efficacy of the diabetes medication is widely reported.


Q: Does Ontin interact with common cold or flu medications?

A: Regulatory documents indicate that no clinically significant pharmacokinetic interaction was observed with the common cold ingredient Pseudoephedrine. It is advised that users check the full list of ingredients in cold and flu products for CNS depressants, as these may have an additive effect.


Q: Does Ontin affect blood pressure?

A: In official safety documents, high blood pressure or increased blood pressure is not listed as a common or uncommon side effect. Rare cardiovascular events may be observed, but a significant impact on blood pressure is not a primary recognized side effect.

How should Ontin be stored and disposed of?

Storage and Disposal Requirements for Ontin (Cetirizine Hydrochloride)

Required Storage Conditions

Ontin must be stored at controlled room temperature, specifically between 20° to 25°C (68° to 77°F). Store the medication in its original container, ensuring it is tightly closed, and protect it from excess heat and moisture. The product must be kept out of the sight and reach of children at all times, as mandated by regulatory guidelines.

Official Disposal Rules

Unused or expired Ontin should be disposed of using an authorized drug take-back program. If a take-back site is unavailable, the product may be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Do not flush Ontin down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ontin found in:

A-Z Index: